Should dying patients have access to experimental, lifesaving drugs? What if those drugs could kill them? It's a tough question, but yesterday the U.S. Court of Appeals for the D.C. circuit made the right decision:
Saying that dying patients have a basic "right of self-preservation,," the court held that drugs that have passed the first phase of FDA review -- which determines whether a product is safe -- should be made available if they might save someone's life.
The 2 to 1 decision by the U.S. Court of Appeals for the District of Columbia Circuit overturned a lower court's ruling. The judges sent the case back to the district court for a full hearing and possibly a trial.
The FDA is being sued by the family of a woman who spent the last years of her life battling for access to experimental cancer drugs before dying at 21. Her father's 2001 Congressional testimony is here.
Reason on Facebook
Reason on Twitter
Reason on YouTube
Reason RSS
Site comments/questions:
Media Inquiries and Reprint Permissions:
(310) 367-6109
Editorial & Production Offices:
3415 S. Sepulveda Blvd.
Suite 400
Los Angeles, CA 90034
(310) 391-2245